Abstract: Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl) quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl) quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.

Abstract: The invention relates to a dry effervescent composition containing inulin, and optionally containing at least one vitaceutical and other active agents. The effervescent products optionally contain lubricants and essential oils and can generate magnesium malate, a therapeutic effector. The invention also relates to a dry effervescent composition containing glucosamine. The invention also encompasses methods of preparing the effervescent compositions of the invention.

Abstract: Pharmaceutical composition for gastric residence, characterized in that it comprises:

Abstract: Methylphenidate or other drugs are provided in a formulation for oral administration that releases the drug in two or more pharmacokinetic spikes, by combining different release forms in a single formulation. In a preferred embodiment for methylphenidate, the first pharmacokinetic spike is achieved by the release of taste-masked methylphenidate which is not enterically coated, while a second pharmacokinetic spike is achieved by the release of methylphenidate in a finely divided form from enterically coated pellets or microparticles formulated for rapid release following dissolution of the enteric coating. A critical aspect of the formulation is the inclusion of excipients that create a burst release following the initial rapid release and uptake. The formulation can be administered as a paste, jelly, suspension, or fast dissolving wafer. To manipulate the dose, the formulation can be provided, for example, as a paste packaged in a tube similar to those used to dispense toothpaste.

Abstract: An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners.

Abstract: The invention relates to an incapacitant mixture comprising PAVA and a solvent, wherein the mixture capable of inducing temporary blindness in a human or animal. The mixture comprises less than 5 per cent PAVA and a solvent.

Abstract: An anti-microbial composition comprising:

Abstract: A denture cleansing composition includes a monoperoxysulfate compound, an effective amount a sequestering agent, such as a citrate compound, for removal of calculus and to provide a pH to the composition in solution (water) of about 3 to 5, and an effective amount of an antimicrobial agent, such as a benzoate compound, to provide antimicrobial activity to the composition to effectively kill bacteria, or other microorganisms found on the dentures. Tests conducted show that the composition is particularly effective in killing microbial strains of Streptococcus mutans, Streptococcus pyogenes, Candida albicans and Actinomyces viscosus within 20 minutes of contact.

Abstract: A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.

Abstract: A fairy ring treatment compound is disclosed comprising a bicarbonate salt fungicide and an acid salt. The treatment process includes the step of spreading the compound over vegetation affected by the fairy ring.

Abstract: The present invention is an additive preparation for use in bodily fluid collection devices. The additive preparation has an additive, an organic acid and a metal carbonate compound. The preparation effervesces when in contact with a body fluid sample, thereby efficiently dispersing in a body fluid sample. The formulation is desirably tabulated to provide an effective, easily stored, and handled preparation. However, a binding or bulking agent may be added to the additive preparation formulation to provide binding and lubricating properties to the formulation. A binding agent enables granulating of the formulation without the forming of a pellet.

Abstract: The present invention relates to a new type of solid balneological preparations for cosmetic, hygienic and therapeutic use, which has both the properties of a solid bath additive and those of liquid products, and is characterized especially by the addition of lipid components, vesicle forming lipids, tensides and, in some cases, mineral salts. Active components, adjuvants such as stabilizers, adsorbing substances, lubricants as well as smoothing and breakdown promoting agents may also be contained therein.

Abstract: The present invention relates to a system that is self-foaming. The self-foaming system has at least two components that are maintained in separate containers. The components produce carbon dioxide when they commingle with each other upon being dispensed from their individual containers. The components are stored separately by being partitioned in separate containers or a container having a chamber for each of the components. The self-foaming system of the present invention has cleansing and cooling properties. The system is mild yet non-irritating because it cools and cleans deeply without interfering with the natural barriers of the skin.

Abstract: Both a process and a method of using peracid compositions, especially mixed peracid systems, to treat field or greenhouse grown plant tissue, seeds, fruits, and growing media and containers. The peracid can lower the natural, plant pathogen and human pathogenic microbial load resulting in less waste to molding, spoilage, and destruction because of pathogenic poisons.

Abstract: Described are solid dose nanoparticulate naproxen formulations having high rates of dissolution. The solid dose nanoparticulate naproxen formulations can comprise an alkali compound, which functions to increase the dissolution rate of the naproxen following administration. Alternatively, the solid dose nanoparticulate naproxen formulation can comprise an alkali compound and an acidic compound, which can react together to form carbon dioxide. The formed carbon dioxide can also aid in increasing the dissolution rate of the naproxen following administration. Also described are solid dose nanoparticulate naproxen formulations having a decreased concentration of a binder/disintegrant agent. Such compositions also provide an increased rate of dissolution of naproxen following administration.

Abstract: A flavor, perfume, coolant or antimicrobial composition comprising an aminoalkylsilicone having an aminosiloxane content of from about 0.1%-2% on a repeating unit basis. The composition provides improved surface residuality, impact and/or antimicrobial efficacy.

Abstract: A spray-dried, granular powder comprising: (i) from about 50% to about 99% of a water-soluble carrier, (ii) from about 1% to about 50% of a hydrophobic silicone oil dispersed within the carrier, wherein the spray-dried powder has a volume average particle size in the range from about 20 .mu.m to about 500 .mu.m, the powder being prepared by spray-drying an aqueous dispersion of the silicone oil and the water-soluble carrier, characterized in that the silicone oil is present in the dispersion in the form of discrete droplets having a volume average droplet size in the range from about 0.5 .mu.m to about 20 .mu.m and that the ratio of the average spray-dried particle size to the average droplet size is at least about 2.5:1. The powder is dry, free-flowing and processable into a punched tablet or other compressed forms, yet efficiently delivers the silicone oil on subsequent dissolution in water.

Abstract: A frozen chlorine dioxide-containing composition comprising a metal chlorite and a protic acid in a frozen aqueous matrix made by freezing a substantially chlorine dioxide-free aqueous solution comprising a metal chlorite at a concentration ranging from about 0.0005% to about 0.5% by weight and a protic acid at a concentration sufficient to lower the pH of the aqueous solution to a value of about 1.8 to about 5.0. The frozen chlorine dioxide-containing composition has a chlorine dioxide concentration of more than about 3 ppm, while the aqueous solution prior to freezing has a chlorine dioxide concentration less than about 3 ppm. The frozen chlorine dioxide-containing composition is used to disinfect substrates by contacting the same with the frozen chlorine dioxide-containing composition. Suitable substrates include food intended for human or animal consumption, such as meat, fish and poultry.

Abstract: A low odor, aqueous, quick acting cold temperature disinfectant solution primarily useful for medical instruments to disinfect within a half hour or less. The composition comprises a reacting or synergistic combination of hydrogen peroxide and from about 1% to 30% by weight of a carboxylic acid/carboxylate salt buffered solution.

Abstract: Disclosed is a non-liquid oral dentifrice composition commonly in the form of powder or tablets which is characterized by an efficacious ratio of carbon dioxide source, xylitol, acid source and silicon dioxide.

Abstract: A denture cleansing agent containing a film forming material for preventing plaque formation. The denture cleansing agent may be a denture cleanser tablet, and the film forming material may be a polyoxyethylene oxide/vinyl acetate copolymer.

Abstract: Active ingredient system for the lipid exchange with target structures; methods for their manufacture and their use; and products containing active ingredient systems of this type are disclosed. The active ingredient system for the transfer of lipophilic and/or amphiphilic components to target structures or from such back to the active ingredient system, as well as to their exchange with the target structures, is formed from at least one lipid component with at least one transfer protein. In the method for the manufacture of the active ingredient system, lipid and protein components are combined into systems in different configurations depending on the purpose of its use and its place of use, whereby the specificity results from the lipid used and the transfer protein employed, as well as the direction of the lipid transfer. Active ingredient systems of this type are used in technology, such as the material technology, in medicine, pharmaceuticals and in the area of cosmetology.

Abstract: The present invention comprises passing a solution of a soluble material, preferably a protein, in a solvent through a continuum of supercritical antisolvent fluid and precipitating the soluble material. This can be conducted by passing the solution through the continuum of supercrital fluid in the form of droplets, which can be sprayed through the supercritical fluid. The plurality of droplets can be passed cocurrently or countercurrently with respect to a stream of antisolvent fluid. Alternatively, the solution can be passed through the continuum of supercritical antisolvent fluid in the form of a thin film or a plurality of fine streams.

Abstract: Its subject is more specifically a process for making suppositories releasing carbon dioxide and endowed with a laxative action in which the fatty substances are melted separately and vegetable lecithin is added into the fluid mass resulting from the melting and then a mineral opacifying agent is incorporated, followed by the pouring of potassium acid tartrate and sodium bicarbonate accompanied by stirring, these two constituents having a particular granulometry, and stirring is then continued until perfect homogeneity is achieved before proceeding with the drawing-off of the fluid suspension.

Abstract: The present invention relates to an effervescent oral care composition with improved interproximal delivery properties. The composition comprises a first composition with about 2.5% by weight of an alkalimetal bicarbonate and a second composition with an acidic compound. Upon bringing the two compositions into contact with each other, e.g. by extruding them from a multicompartment container through a single outlet orifice, the alkalimetal bicarbonate and the acidic compound react with each other, causing an effervescent effect. By using 0.02% to less than 0.5% by weight, calculated on the total weight of the oral care composition, of the acidic compound, the interproximal delivery properties of the composition are significantly improved.

Abstract: A solid state bath agent containing Na2CO3 (Sodium Carbonate), NaHCO3 (Sodium Bicarbonate), Na2SO4 (Sodium Sulfate), Citric acid, CMC (Carboxymethyl Cellulose), Bactericide, Silicone oil, Vitamin E, Vitamin C, AHA and fragrance. Na2CO3, NaHCO3, Na2SO4 and Citric acid are dried by hot air, then mixed with the other materials and then pressed into individual bath cakes (bath balls), and then the finished individual bath cakes (bath balls) are well packed in an air-tight sealing container.

Abstract: A denture cleansing composition comprising an inorganic persalt bleaching agent, an effervescence generator and an aminoalkysilicone. The composition provides improved antiplaque, cleasing and antibacterial activity together with excellent physical and in-use performance characteristics.

Abstract: A composition and method for treating epidermal wounds utilizes an aqueous solution of sodium sulphate, sodium carbonate, sodium bicarbonate, sodium chloride and ichthammol.

Abstract: A non-aqueous liquid plaque adsorbent oral or effervescent dentifrice composition comprising a non-aqueous carbon dioxide source selected from bicarbonate salt, carbonate salt and mixtures thereof, a non-aqueous, water soluble acid source selected from organic acid, partial salt thereof and mixtures thereof, and a carrier adsorbent. Optionally, the composition can include flavoring agent, artificial, non-caloric sweetener, surface active agent, anti-bacterial agent, astringent agent, desensitizing agent, fluoride containing anti-caries agent, gelling agent, chloropyhyllin salt, coloring agent, hydrogen peroxide source and/or excipient. The effervescent dentifrice is preferably employed as one component of a kit also including a debriding product, a hydrogen peroxide product and a bicarbonate dentifrice, the components of the kit being used in combination on a daily basis to synergistically achieve enhanced preventative and remedial oral hygiene.

Abstract: This invention is directed to a novel effervescing foaming bath shape or solid composition. More particularly, this invention pertains to a novel effervescing or foaming bath ball composition which has rapid mixing and production time, and antiseptic and skin conditioning properties. A bath shape or sold formulation comprising: (a) between 40 to 90% by weight of sodium bicarbonate; (b) between 5 to 50% by weight of organic acid; and (c) between 0.5 to 15% weight of alcohol. The formulation can also include (d) between 0.5 to 10% of vegetable oil; (e) between about 0.01 to 0.1 % weight of FD&C certified color to provide a pleasing color to the formulation; (f) between about 0.01 to 10% weight of fragrance to provide an appealing aroma to the composition, and a surfactant.

Abstract: A chewable softgel formulation to deliver water soluble vitamins and supplements to improve dissolution time and availability. The formulation contains components design for the elimination and prevention of dental caries, bad breath, gingivitis and also inner ear infections.

Abstract: This invention relates to (R)-5-(aminosulphonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole and its pharmaceutically acceptable salts. This compound is particularly useful in treating disorders arising from deficient serotonergic neurotransmission, especially migraine.

Abstract: A readily, water-dispersible pesticide formulation in the form of a thick paste containing 1 to 80% by weight of the pesticide, 0.30 to 2.0% by weight of a micropore-generating agent and 30 to 50% by weight of effervescent agents the percentages being based on the total weight of the formulation.

Abstract: This invention relates to microbicidal and sanitizing soap compositions. More particularly, the invention relates to microbicidal and sanitizing soap compositions that incorporate agents with tuberculocidal properties in ready-to-use form that has gel properties or thixotropic-properties and to soap concentrate compositions suitable for dilution in or with water or non-aqueous diluent to produce gel-like or thixotropic solutions or dispersions ranging from free flowing to solidified forms. The ready-to-use compositions and the concentrate compositions are applied for purposes of personal or animal hygiene or sanitizing on hair, hands and skin or other body parts, or are applied on inanimate surfaces and objects that need to be sanitized.

Abstract: Pharmaceutical formulations of cefaclor, suitable for the direct-compression manufacture of dispersible tablets, containing the antibiotic cefaclor in an amount between 35% and 50% by weight of the total weight of the formulation, along with suitable excipients and coadjuvants selected from disintegrators, diluents, lubricants, antiadherents, sweeteners, fragrances and, optionally, flavorings, opacifiers and colorants. Said formulations are suitable for the manufacture of dispersible tablets which disintegrate in less than three minutes in water at 19.degree.-21.degree. C., and are suitable for the treatment of infections caused by bacteria strains sensitive to cefaclor.

Abstract: A two component efficacious dentifrice composition, having a first alkali metal bicarbonate containing dentifrice component and a second acid-containing dentifrice component; the first and second components being separated prior to use; wherein, the pH of the two components when combined upon application to the teeth is between about 6.0 and about 7.1; whereby, the dentifrice provides enhanced removal of plaque growth and a tingly mouth feel.

Abstract: A method for preparation of a medical solution from water and a plurality of concentrates, including at least one acid in gaseous form, comprises the steps of transporting the water from a source through a main conduit and successively adding the plurality of concentrates to the water in the main conduit at a plurality of predetermined points positioned along the main conduit.

Abstract: A non-aqueous liquid plaque adsorbent oral or effervescent dentifrice composition comprising a non-aqueous carbon dioxide source selected from bicarbonate salt, carbonate salt and mixtures thereof, a non-aqueous, water soluble acid source selected from organic acid, partial salt thereof and mixtures thereof, and a carrier adsorbent. Optionally, the composition can include flavoring agent, artificial, non-caloric sweetener, surface active agent, anti-bacterial agent, astringent agent, desensitizing agent, fluoride containing anti-caries agent, gelling agent, chloropyhyllin salt, coloring agent, hydrogen peroxide source and/or excipient. The effervescent dentifrice is preferably employed as one component of a kit also including a debriding product, a hydrogen peroxide product and a bicarbonate dentifrice, the components of the kit being used in combination on a daily basis to synergistically achieve enhanced preventative and remedial oral hygiene.

Abstract: A blood oxygenator having a substantially cylindrical structure provided with an inner wall or core and an outer wall that define an oxygenation chamber. The oxygenation chamber contains a hollow fiber bundle comprised of hollow microporous semi-permeable fibers which are meant to be affected externally by the blood that flows in the oxygenation chamber. The oxygenation chamber is provided with inlet and outlet paths for connection to the outside. The hollow fibers are embedded, at their ends, in rings of polyurethane resin known as potting and are connected to gas inlet and outlet chambers respectively for the intake of oxygen and for the discharge of the carbon dioxide. The structure includes ribs that extend from the inner wall of the structure and are divided into multiple sets that run longitudinally along the entire length of the core generally parallel with the axis of the core.

Abstract: The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e.g., wounds, burns, etc.), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.

Abstract: Disclosed is a non-liquid oral dentifrice composition commonly in the form of powder or tablets which is characterized by an efficacious ratio of carbon dioxide source, xylitol, acid source and silicon dioxide.

Abstract: A method and an apparatus for preparation of a medical solution from water and a plurality of concentrates, including at least one acid in gaseous form, comprises the steps of transporting the water from a source through a main conduit and successively adding the plurality of concentrates to the water in the main conduit at a plurality of predetermined points positioned along the main conduit. The apparatus for preparing the medical solution includes a source for supplying the gaseous acid and other concentrates to the plurality of predetermined points along the main conduit, wherein the plurality of predetermined points includes a gas inlet for injecting the acid in gaseous form supplied from the gas source into the main conduit.

Abstract: Active ingredient system for the lipid exchange with target structures; methods for their manufacture and their use; and products containing active ingredient systems of this type are disclosed. The active ingredient system for the transfer of lipophilic and/or amphophilic components to target structures or from such back to the active ingredient system, as well as to their exchange with the target structures, is formed from at least one lipid component with at least one transfer protein. In the method for the manufacture of the active ingredient system, lipid and protein components are combined into system in different configurations depending on the purpose of its use and its place of use, whereby the specificity results from the lipid used and the transfer protein employed, as well as the direction of the lipid transfer. Active ingredient system of this type are used in technology, such as the material technology, in medicine, pharmaceuticals and in the area of cosmetology.

Abstract: Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which aspirin loses its molecular structure chiefly by losing the acetyl group. The latter is accompanied by formation of acetic acid, the mixture developing its characteristic acetic odor. In both cases, such compositions become entirely unsuitable for all practical commercial and medicinal purposes. Yet, when preparation of water-soluble aspirin compositions is desired, it is impossible to avoid the use of alkaline compounds. This is because the only known method of converting aspirin into soluble form is by means of reacting it with an alkaline compound to form the soluble salt of aspirin.

Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.

Abstract: Pharmaceutical formulations of fluoxetine or an acid addition salt thereof, suitable for manufacturing dispersible tablets by direct compression and comprising, in addition to the active ingredient, the appropriate excipients and coadjuvants, selected from among disintegrants, diluents, lubricants, anti-adherents, sweeteners, flavorings and, optionally, colorants.Said formulations are suitable for manufacturing dispersible tablets which disintegrate in less than three minutes in water at 19.degree. C.-21.degree. C., and are appropriate for treatment of depression.

Abstract: A stabilized, essentially sodium free, alkaline and aspirin combination compound which is readily soluble in a preselected fluid, which when dissolved forms potassium acetylsalicylate. Such alkaline and aspirin combination compound consisting essentially of aspirin, having a predetermined particle size. Such aspirin being present in the alkaline and aspirin combination compound generally within a range of between about 325.0 mg and about 1,000.0 mg per unit dose. A preselected alkaline compound is present in such alkaline and aspirin combination compound generally within a range of between about 250.0 mg and about 3,000.0 mg per unit dose. The preselected alkaline compound having a ph generally within a range of between about 8.0 and 10.0 and such preselected alkaline compound being present in this alkaline and aspirin combination compound in a molar amount which is greater than a molar amount required to neutralize the aspirin.

Abstract: Pharmaceutical compositions having analgesic activity containing (S)-2-(6-methoxy-2-naphthyl)-propionic acid as active ingredient and arginine, useful for the preparation of pharmaceutical forms for oral route, are described,

Abstract: A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.

Abstract: A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.